Robert Waltermire
Corporate Officer/Principal chez MADRIGAL PHARMACEUTICALS, INC.
Fortune : 1 M $ au 31/05/2024
Profil
Robert Waltermire is currently the Chief Pharmaceutical Development Officer at Madrigal Pharmaceuticals, Inc. He previously worked at Venatorx Pharmaceuticals, Inc. as the Senior Vice President-CMC from 1988 to 2020.
Waltermire completed his undergraduate degree at Franklin & Marshall College in 1984 and obtained his doctorate from the University of Maryland in 1988.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/06/2024 | 5 500 ( 0,03% ) | 1 M $ | 31/05/2024 |
Postes actifs de Robert Waltermire
| Sociétés | Poste | Début |
|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02/08/2021 |
Anciens postes connus de Robert Waltermire
| Sociétés | Poste | Fin |
|---|---|---|
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 01/01/2020 |
Formation de Robert Waltermire
| Franklin & Marshall College | Undergraduate Degree |
| University of Maryland | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Commercial Services |
